Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Selected Articles from This Issue
    Mol Cancer Ther April 1 2020 19 (4) 973-973;

MCT First Disclosures

  • MCT First Disclosures
    Editorial Molecular Cancer Therapeutics: A Central Hub for First Disclosures in Cancer
    Mol Cancer Ther April 1 2020 19 (4) 975-975; DOI:10.1158/1535-7163.MCT-20-0131

  • Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
    MCT First Disclosures | AuthorChoice
    Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
    Anita Kulukian, Patrice Lee, Janelle Taylor, Robert Rosler, Peter de Vries, Daniel Watson, Andres Forero-Torres and Scott Peterson
    Mol Cancer Ther April 1 2020 19 (4) 976-987; DOI:10.1158/1535-7163.MCT-19-0873

  • Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
    MCT First Disclosures
    Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
    Helen Kotanides, Rose Marie Sattler, Maria B. Lebron, Carmine Carpenito, Juqun Shen, Jingxing Li, David Surguladze, Jaafar N. Haidar, Colleen Burns, Leyi Shen, Ivan Inigo, Anthony L. Pennello, Amelie Forest, Xinlei Chen, Darin Chin, Andreas Sonyi, Michael Topper, Lauren Boucher, Prachi Sharma, Yiwei Zhang, Douglas Burtrum, Ruslan D. Novosiadly, Dale L. Ludwig, Gregory D. Plowman and Michael Kalos
    Mol Cancer Ther April 1 2020 19 (4) 988-998; DOI:10.1158/1535-7163.MCT-19-0893

Review

  • Review
    A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting
    Lihua Shu, Dongsheng Wang, Nabil F. Saba and Zhuo G. Chen
    Mol Cancer Ther April 1 2020 19 (4) 999-1007; DOI:10.1158/1535-7163.MCT-19-0660

Small Molecule Therapeutics

  • Small Molecule Therapeutics
    Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1α in Prostate Cancer Cells
    Kuntal Biswas, Sukumar Sarkar, Neveen Said, David L. Brautigan and James M. Larner
    Mol Cancer Ther April 1 2020 19 (4) 1008-1017; DOI:10.1158/1535-7163.MCT-19-0777

  • Small Molecule Therapeutics
    Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance
    Marco H. Hofmann, Rajeswaran Mani, Harald Engelhardt, Maria A. Impagnatiello, Sebastian Carotta, Marc Kerenyi, Seila Lorenzo-Herrero, Jark Böttcher, Dirk Scharn, Heribert Arnhof, Andreas Zoephel, Renate Schnitzer, Thomas Gerstberger, Michael P. Sanderson, Girish Rajgolikar, Swagata Goswami, Sumithira Vasu, Peter Ettmayer, Segundo Gonzalez, Mark Pearson, Darryl B. McConnell, Norbert Kraut, Natarajan Muthusamy and Jürgen Moll
    Mol Cancer Ther April 1 2020 19 (4) 1018-1030; DOI:10.1158/1535-7163.MCT-19-0789

  • Small Molecule Therapeutics
    Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
    Sophie Piperno-Neumann, James Larkin, Richard D. Carvajal, Jason J. Luke, Gary K. Schwartz, F. Stephen Hodi, Marie-Paule Sablin, Alexander N. Shoushtari, Sebastian Szpakowski, Niladri Roy Chowdhury, A. Rose Brannon, Thiruvamoor Ramkumar, Leanne de Koning, Adnan Derti, Caroline Emery, Padmaja Yerramilli-Rao and Ellen Kapiteijn
    Mol Cancer Ther April 1 2020 19 (4) 1031-1039; DOI:10.1158/1535-7163.MCT-19-0098

Large Molecule Therapeutics

  • Large Molecule Therapeutics
    Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
    Sun K. Ho, Zhenghai Xu, Archana Thakur, Melvin Fox, Siu Sze Tan, Enrico DiGiammarino, Li Zhou, Mien Sho, Belinda Cairns, Vivian Zhao, Mengli Xiong, Josue Samayoa, Charles M. Forsyth, David B. Powers, Debra T. Chao, Diane Hollenbaugh, Hamsell M. Alvarez and Yoshiko Akamatsu
    Mol Cancer Ther April 1 2020 19 (4) 1040-1051; DOI:10.1158/1535-7163.MCT-19-0608

  • Large Molecule Therapeutics | AuthorChoice
    Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies
    Lidia Nazarova, Hanine Rafidi, Danielle Mandikian, Gregory Z. Ferl, James T. Koerber, Christopher W. Davies, Sheila Ulufatu, Jason Ho, Jeffrey Lau, Shang-Fan Yu, James Ernst, Jack D. Sadowsky and C. Andrew Boswell
    Mol Cancer Ther April 1 2020 19 (4) 1052-1058; DOI:10.1158/1535-7163.MCT-19-1015

  • Large Molecule Therapeutics | AuthorChoice
    Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models
    Ulrike Weyer-Czernilofsky, Marco H. Hofmann, Katrin Friedbichler, Rosa Baumgartinger, Paul J. Adam, Flavio Solca, Norbert Kraut, Holly M. Nguyen, Eva Corey, Gang Liu, Cynthia C. Sprenger, Stephen R. Plymate and Thomas Bogenrieder
    Mol Cancer Ther April 1 2020 19 (4) 1059-1069; DOI:10.1158/1535-7163.MCT-19-0378

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
    Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy
    Maike Zimmermann, Tao Li, Thomas J. Semrad, Chun-Yi Wu, Aiming Yu, George Cimino, Michael Malfatti, Kurt Haack, Kenneth W. Turteltaub, Chong-xian Pan, May Cho, Edward J. Kim and Paul T. Henderson
    Mol Cancer Ther April 1 2020 19 (4) 1070-1079; DOI:10.1158/1535-7163.MCT-19-0133

Models and Technologies

  • Models and Technologies
    High-Throughput Generation of Bispecific Binding Proteins by Sortase A–Mediated Coupling for Direct Functional Screening in Cell Culture
    Fabio Andres, Martin Schwill, Ykelien L. Boersma and Andreas Plückthun
    Mol Cancer Ther April 1 2020 19 (4) 1080-1088; DOI:10.1158/1535-7163.MCT-19-0633

Back to top
PreviousNext
Molecular Cancer Therapeutics: 19 (4)
April 2020
Volume 19, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Issue Highlights

  • Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
  • Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
  • A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting
  • Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy

Jump to

  • Highlights
  • MCT First Disclosures
  • Review
  • Small Molecule Therapeutics
  • Large Molecule Therapeutics
  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
  • Models and Technologies
Advertisement
  • Most Cited
  • Most Read
Loading
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • Truncated BRCA2 Contributes to PARPi Resistance
  • ERPAS to Predict Response to Endocrine Therapy
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Sialoglycan mAb for Cancer Immunotherapy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement